smaller than 3 cm.2 Although most renal tumors associated with BHDS behave in an indolent manner, the presence of clear cell components in renal tumors could reflect a worse prognosis.3 As FLCN is linked to the mammalian target of rapamycin pathway, mammalian target of rapamycin inhibitors could be effective for BHDS patients with metastasis. 2 The prompt preparation of international medical guideline for diagnosis and management in BHDS-associated renal tumors might be desirable. Partial nephrectomy is the preferred choice for the treatment of small renal tumors (T1a, T1b). One of the recognized complications of this procedure is urine leak, which occurs in 1.4-17.4% of patients, 1 and urine fistula with an incidence of 3-6%. 2 These can normally be managed conservatively. On rarer occasions, small renal tumors need to be managed with percutaneous drain, stent, nephrostomy or total nephrectomy as a last resort. We present a case of a chronic nephrocutaneous fistula resulting after a prolonged urine leak from an open partial nephrectomy, which was managed with an innovative and novel technique. This involved insertion of a percutaneous nephrostomy and injection of fibrin sealant into the fistula tract.
Management of a patient with a chronic nephrocutaneous fistula after partial nephrectomy using a novel techniqueA 69-year-old man presented with an incidental finding of a 5.5-cm, left-sided, mid-zone renal mass suspicious of T1b renal cell carcinoma (Fig. 1). His comorbidities included hypertension. The patient underwent an open partial nephrectomy during which the collecting system was opened (ischemic time 20 min). The defect was closed with an absorbable monofilament suture using a two-layer technique, a hemostatic matrix and an absorbable hemostatic agent bolster.Postoperatively, there was a high output of urine from the drain. At 2 weeks, the leak persisted; therefore, a cystoscopy and retrograde study were carried out, which showed a leak in the upper pole calyx. A ureteric stent (6-Fr 24 cm) and a urethral catheter were inserted. The drain, ureteric stent and catheter were removed once the leak dried at 5 weeks. The patient was found to have a nephrocutaneous fistula at 12 weeks confirmed by a fistulagram (Fig. 1). At 24 weeks, another ureteric stent (6-Fr 26 cm) and urethral catheter were inserted. DOI: 10.1111/iju.12641 At 28 weeks, the urine leak persisted; therefore, the stent was removed, and a retrograde study was carried out. A nephrostomy (10-Fr) was inserted into the lower pole calyx, away from the area of previous surgery (Fig. 1). The sinus tract at the upper pole was then dilated to 30-Fr in case a nephroscopy would be required to inject the sealant under vision. This was carried out from the skin down to the kidney under image intensifier guidance. Then, 4 mL of a fibrin sealant (Teeseal; Baxter Healthcare Corporation, Liverpool, UK) was injected blindly into the sinus tract and the leaking point, using an applicator that stops fibrin from migrating out of the tract (Duplospray MIS; Baxter...